Amarin Still Suspends FY22 Guidance On Generic Challenges

• Amarin Corporation plc (NASDAQ: AMRN) continues suspending 2022 revenue guidance citing the ongoing global impact of COVID-19, the uncertainty resulting from the impact of generic IPE availability in the U.S., and challenges for most drugs seeking market access in Europe.

• "In the second quarter of 2022, we made important progress on our long-term growth strategy. Our achievements give us confidence in the direction of and opportunities for Amarin during the remainder of 2022 and into 2023," said CEO Karim Mikhail.

• Amarin reiterates that current cash, investments, and other assets are adequate to support continued operations, including European launch activities for at least the next twelve months.

• The company reported Q2 sales of $94.4 million, a decrease of 39% driven by a decline in volume and net selling price due to an increase in generic competition in the U.S.

• During Q2, there were three generic competitors in the U.S. market compared to one a year ago.

• Amarin's gross margin on net product revenue was 46%, compared with 79% a year ago. The adjusted gross margin was 72%.

• Amarin posted an adjusted EPS loss of $(0.09), a shift from a profit of $0.03 a year ago and missing the consensus loss of $(0.06).

• Price Action: AMRN shares are down 1.57% at $1.30 during the market session on the last check Wednesday.

See more from Benzinga

• Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.